Treatment of lysosomal storage disorders : progress with enzyme replacement therapy (Q37025890)

17 August 2017

1 reference

title

Treatment of lysosomal storage disorders : progress with enzyme replacement therapy (English)

1 reference

enzyme replacement therapy

17 August 2017

0 references

author name string

Marianne Rohrbach

series ordinal

1

1 reference

PubMed ID

18062719

17 August 2017

Joe T R Clarke

series ordinal

2

1 reference

17 August 2017

1 January 2007

1 reference

17 August 2017

1 reference

17 August 2017

67

1 reference

17 August 2017

2697-2716

1 reference

17 August 2017

18

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200767180-00005

17 August 2017

0 references

cites work

Lysosomal enzyme targeting

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767180-00005

Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767180-00005

Narrative review: Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767180-00005

Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767180-00005

A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies

21 January 2018

1 reference

12 December 2020

Pompe disease in infants and children

1 reference

12 December 2020

Guidance on the use of miglustat for treating patients with type 1 Gaucher disease

1 reference

12 December 2020

An update on the frequency of mucopolysaccharide syndromes in British Columbia

1 reference

12 December 2020

Natural history and treatment of renal involvement in Fabry disease.

1 reference

12 December 2020

Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease.

1 reference

12 December 2020

Enzyme replacement therapy in feline mucopolysaccharidosis I.

1 reference

12 December 2020

Bone-Marrow Transplantation in the Maroteaux–Lamy Syndrome (Mucopolysaccharidosis Type VI)

1 reference

12 December 2020

Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.

1 reference

12 December 2020

A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease

1 reference

12 December 2020

Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk

1 reference

12 December 2020

Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications.

1 reference

12 December 2020

Glycogenosis type II (Pompe). The fourth autopsy case in Japan.

1 reference

12 December 2020

Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease

1 reference

12 December 2020

Biogenesis of transport intermediates in the endocytic pathway

1 reference

12 December 2020

Dense core lysosomes can fuse with late endosomes and are re-formed from the resultant hybrid organelles

1 reference

12 December 2020

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

1 reference

12 December 2020

High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews

1 reference

12 December 2020

The vascular dementia of Fabry's disease

1 reference

12 December 2020

METABOLISM OF GLUCOCEREBROSIDES. II. EVIDENCE OF AN ENZYMATIC DEFICIENCY IN GAUCHER'S DISEASE.

1 reference

12 December 2020

Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease

1 reference

12 December 2020

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

1 reference

12 December 2020

N-glycans of recombinant human acid alpha-glucosidase expressed in the milk of transgenic rabbits

1 reference

12 December 2020

Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease

1 reference

12 December 2020

The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women

1 reference

12 December 2020

[Fetal pathology in Fabry's disease and mucopolysaccharidosis type I]

1 reference

12 December 2020

Gaucher disease: lessons from a decade of therapy

1 reference

12 December 2020

The cell biology of lysosomal storage disorders

1 reference

12 December 2020

The frequency of lysosomal storage diseases in The Netherlands.

1 reference

12 December 2020

Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk

1 reference

12 December 2020

Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, o

1 reference

12 December 2020

Recombinant human alpha-glucosidase from rabbit milk in Pompe patients.

1 reference

12 December 2020

The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease.

1 reference

12 December 2020

Cardiac involvement in Anderson-Fabry disease.

1 reference

12 December 2020

Functions of lysosomes

1 reference

12 December 2020

Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase.

1 reference

12 December 2020

Long-term outcome of Hurler syndrome following bone marrow transplantation.

1 reference

12 December 2020

Murine MPS I: insights into the pathogenesis of Hurler syndrome.

1 reference

12 December 2020

A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)

1 reference

12 December 2020

Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease

1 reference

12 December 2020

Treatment with miglustat reverses the lipid-trafficking defect in Niemann-Pick disease type C.

1 reference

12 December 2020

Nervous system in Pompe's disease. Ultrastructure and biochemistry

1 reference

12 December 2020

Replacement Therapy for Inherited Enzyme Deficiency

1 reference

12 December 2020

Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).

1 reference

12 December 2020

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

1 reference

12 December 2020

Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy

1 reference

12 December 2020

Prevalence of lysosomal storage disorders

1 reference

12 December 2020

Follow-up of nine patients with Hurler syndrome after bone marrow transplantation.

1 reference

12 December 2020

Secretory Lysosome Biogenesis in Cytotoxic T Lymphocytes from Normal and Chediak Higashi Syndrome Patients

1 reference

12 December 2020

Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial

1 reference

12 December 2020

Gaucher disease phenotype

1 reference

12 December 2020

Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry

1 reference

12 December 2020

Processing of the phosphorylated recognition marker in lysosomal enzymes. Characterization and partial purification of a microsomal alpha-N-acetylglucosaminyl phosphodiesterase

1 reference

12 December 2020

A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)

1 reference

12 December 2020

Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial.

1 reference

12 December 2020

Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II

1 reference

12 December 2020

The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels.

1 reference

12 December 2020

Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta

1 reference

12 December 2020

Mannose 6-phosphate receptors: new twists in the tale

1 reference

12 December 2020

Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources

1 reference

12 December 2020

Home treatment with intravenous enzyme replacement therapy for Gaucher disease: an international collaborative study of 33 patients

1 reference

12 December 2020

The long-term international safety experience of imiglucerase therapy for Gaucher disease

1 reference

12 December 2020

New insights in cardiac structural changes in patients with Fabry’s disease

1 reference

12 December 2020

Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis

1 reference

12 December 2020

UDP-N-acetylglucosamine: lysosomal enzyme N-acetylglucosamine-1-phosphotransferase

1 reference

12 December 2020

Echocardiographic abnormalities and disease severity in Fabry's disease.

1 reference

12 December 2020

Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies

1 reference

12 December 2020

Incidence of the mucopolysaccharidoses in Northern Ireland

1 reference

12 December 2020

Agalsidase-beta therapy for advanced Fabry disease: a randomized trial

1 reference

12 December 2020

Glucosylceramide transfer from lysosomes--the missing link in molecular pathology of glucosylceramidase deficiency: a hypothesis based on existing data

1 reference

12 December 2020

Modifying exogenous glucocerebrosidase for effective replacement therapy in Gaucher disease.

1 reference

12 December 2020

Cerebrovascular complications of Fabry's disease

1 reference

12 December 2020

Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy

1 reference

12 December 2020

Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation

1 reference

12 December 2020

Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).

1 reference

12 December 2020

Gaucher disease: enzyme therapy in the acute neuronopathic variant

1 reference

12 December 2020

Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group

1 reference

12 December 2020

Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres

1 reference

12 December 2020

Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease

1 reference

12 December 2020

Lysosomal storage diseases: natural history and ethical and economic aspects

1 reference

12 December 2020

Enzyme-replacement therapy in mucopolysaccharidosis I.

1 reference

12 December 2020

The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature

1 reference

12 December 2020

The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement

1 reference

12 December 2020

10.2165/00003495-200767180-00005

Identifiers

DOI

1 reference

PubMed ID

18062719

Dimensions Publication ID

17 August 2017

0 references

1 reference

PubMed ID

18062719